10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2012 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2012 | Dec 31, 2011 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 230,276 | 483,610 |
| Marketable securities | 77,819 | 43,332 |
| Accounts receivable - trade, net | 593,207 | 28,254 |
| Accounts receivable from Sanofi | 99,913 | 74,781 |
| Deferred tax assets | 148,134 | |
| Prepaid expenses and other current assets | 56,663 | 35,800 |
| Total current assets | 1,206,012 | 665,777 |
| Restricted cash and marketable securities | 8,186 | 7,721 |
| Marketable securities | 271,230 | 275,887 |
| Property, plant, and equipment, at cost, net of accumulated depreciation and amortization | 379,940 | 367,955 |
| Deferred tax assets | 192,022 | |
| Other assets | 23,100 | 6,243 |
| Total assets | 2,080,490 | 1,323,583 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 111,345 | 95,625 |
| Deferred revenue from Sanofi, current portion | 17,022 | 20,011 |
| Deferred revenue - other, current portion | 33,809 | 31,629 |
| Facility lease obligations, current portion | 1,374 | 1,006 |
| Total current liabilities | 163,550 | 148,271 |
| Deferred revenue from Sanofi | 76,520 | 86,017 |
| Deferred revenue - other | 131,822 | 162,593 |
| Facility lease obligations | 159,436 | 159,508 |
| Convertible senior notes | 296,518 | 275,019 |
| Other long term liabilities | 7,259 | 6,443 |
| Total liabilities | 835,105 | 837,851 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' equity: | ||
| Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none | ||
| Additional paid-in capital | 1,763,508 | 1,754,824 |
| Accumulated deficit | (517,054) | (1,267,323) |
| Accumulated other comprehensive loss | (1,166) | (1,862) |
| Total stockholders' equity | 1,245,385 | 485,732 |
| Total liabilities and stockholders' equity | 2,080,490 | 1,323,583 |
| Class of Stock | ||
| Class A Stock, convertible, $.001 par value; 40,000,000 shares authorized; shares issued and outstanding - 2,069,187 at December 31, 2012 and 2,109,512 at December 31, 2011 | ||
| Common stock | 2 | 2 |
| Common Stock, $.001 par value; 160,000,000 shares authorized; shares issued and outstanding - 95,223,525 at December 31, 2012 and 90,692,071 at December 31, 2011 | ||
| Common stock | 95 | 91 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |